Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT04246047
Active Not Recruiting
This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/27/2024
Locations: GSK Investigational Site, Yuma, Arizona +143 locations
Conditions: Multiple Myeloma
Register for Updates
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
NCT06207123
Recruiting
The purpose of this study is to learn more about LP-118 (an experimental drug) and its side effects and decide on acceptable doses. The purpose of this study is to determine if LP-118 can be given safely with another medicine called ponatinib, that is FDA-approved for the treatment of acute lymphoblastic leukemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/25/2024
Locations: University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois
Conditions: Acute Leukemia, Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Register for Updates
Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma
NCT04756401
Active Not Recruiting
This phase II trial studies the effect of selinexor when combined with carfilzomib, daratumumab, and dexamethasone in treating patients with high-risk multiple myeloma that has come back (recurrent) or has not responded to treatment (refractory) and who have received 1-3 prior lines of therapy. Selinexor may stop the growth of cancer cells by blocking a protein called CRM1 that is needed for cell growth. Carfilzomib is a type of drug called a proteasome inhibitor. A proteasome is a protein found... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/24/2024
Locations: Hackensack University Medical Center, Hackensack, New Jersey +3 locations
Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Register for Updates
Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma
NCT02939183
Completed
A study evaluating two new formulations of oprozomib plus pomalidomide and dexamethasone in participants with relapsed refractory multiple myeloma.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
09/20/2024
Locations: Research Site, West Hollywood, California +19 locations
Conditions: Relapsed or Refractory Multiple Myeloma
Register for Updates
Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
NCT02441686
Active Not Recruiting
This research study is evaluating a combination of three drugs called lenalidomide, subcutaneous (injection under the skin) bortezomib, and dexamethasone (RVD) as a possible treatment for multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/20/2024
Locations: Colorado Blood Cancer Institute, Denver, Colorado +7 locations
Conditions: Multiple Myeloma
Register for Updates
Ridge Preservation With FDBA (Freeze Dried Bone Allograft) Using Dexamethasone vs. Saline
NCT06556095
Recruiting
Following the removal of a tooth, a bone graft is often placed in the socket to try to maintain the volume of bone that was there when the tooth was present so that the bone does not "shrink". The bone graft is kept in place with a small piece of material over the top of the tooth socket and with stitches. This procedure is called "Ridge Preservation". Many different materials are used for ridge preservation, including bone allografts (bone grafts derived from a human tissue donor). These bone a... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
09/18/2024
Locations: UT Health Science Center at San Antonio, School of Dentistry, San Antonio, Texas
Conditions: Bone Graft, Tooth Extraction
Register for Updates
Low Dose Versus Standard Dose Dexamethasone for Reduction of Swelling in Patients with Primary or Metastatic Brain Tumors
NCT05139043
Active Not Recruiting
This phase II trial studies whether low dose dexamethasone works as well as standard dose dexamethasone to reduce brain swelling after brain surgery in patients with primary brain tumors or cancer that has spread from other places in the body to the brain (metastatic). Surgery is an important part of the treatment of brain tumors; however, it results in injury to surrounding brain tissue, leading to brain swelling. Dexamethasone is effective for controlling the swelling of the brain; however, de... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/17/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Malignant Brain Neoplasm, Metastatic Malignant Neoplasm in the Brain, Recurrent Malignant Brain Neoplasm
Register for Updates
Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
NCT02253316
Active Not Recruiting
The purpose of this research study is to evaluate a treatment regimen called IRD which will be given to participants after their stem cell transplant in an effort to help prolong the amount of time the participants are disease-free after transplant. IRD is a three-drug regimen consisting of ixazomib, lenalidomide (also called Revlimid), and dexamethasone. After 4 cycles of IRD, the participants will be randomized to receive maintenance therapy either with ixazomib or lenalidomide.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
09/17/2024
Locations: City of Hope, Duarte, California +9 locations
Conditions: Multiple Myeloma
Register for Updates
Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma
NCT05773664
Withdrawn
This phase I trial tests the safety, side effects, and best dose of dexamethasone when given with azeliragon in managing cerebral edema after surgery (post-resection) in patients with glioblastoma. Cerebral edema is a pathological increase in the water mass contained within the brain interstitial space. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Az... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/17/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Glioblastoma, Malignant Glioma
Register for Updates
Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM
NCT02375555
Completed
This research study is evaluating a combination of four drugs -- lenalidomide, bortezomib, dexamethasone and elotuzumab -- as therapy for newly diagnosed multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/13/2024
Locations: Emory University, Atlanta, Georgia +6 locations
Conditions: Multiple Myeloma
Register for Updates
Extended and Controlled Release Liposomal Formulated Dexamethasone for Chronic Knee OA Pain
NCT04123561
Completed
Phase 3 randomized, double-blind, placebo- and active comparator-controlled study of TLC599.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
09/12/2024
Locations: Cahaba Research, Inc, Birmingham, Alabama +45 locations
Conditions: Osteoarthritis of the Knee
Register for Updates
Selinexor and Backbone Treatments of Multiple Myeloma Patients
NCT02343042
Recruiting
This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to be evaluated are: * Arm 1: Selinexor + dexamethasone + pomalidomide (SPd); enrollment complete * Arm 2: Selinexor + dexamethasone + bortezomib (SVd); enrollment complete * Arm 3: Selinexor + dexamethas... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/12/2024
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +23 locations
Conditions: Multiple Myeloma
Register for Updates